Shots:
- Samsung Bioepis to directly commercialize Opuviz 40 mg/mL solution for injection in a vial, a biosimilar version of Eylea (aflibercept), across the EU
- Opuviz is indicated to treat wet age-related macular degeneration (AMD), visual impairment due to macular oedema secondary to retinal vein occlusion (RVO; branch or central RVO), diabetic macular oedema (DME), and myopic choroidal neovascularization (myopic CNV)
- Additionally, Opuviz 40 mg/mL pre-filled syringe received a positive CHMP opinion in Nov 2025 and is expected to launch in the market in Q3’26
Ref: Businesswire | Image: Samsung Bioepis | Press Release
Related News: Samsung Bioepis Introduces its Ustekinumab Biosimilar in Japan with NIPRO CORPORATION
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
